HOW WE HELP
NET Cancer is the FASTEST growing class of CANCER worldwide
HELP US HELP OTHERSNeuroendocrine Tumours (NETs) Overview
- Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
- NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
- NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
- NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
- The cause of NETs is currently unknown.
CONTACT US
SUPPORT LINES:
416-628-3189
Toll Free: 1-844-628-6788
EMAIL:
CNETS NEWS
LUTATHERA® Funded in Nova Scotia
As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed [...]
#HoofingIt launches at Peggy’s Cove July 1
HOOFING IT - The summer-long fundraiser launched at Peggy's Cove on July 1st. Sharon Needham, lung neuroendocrine cancer survivor and advocate; family, friends, supporters kicked-off HOOFING IT with a 5km walk along Peggy's Cove [...]
#HoofingIt fundraiser launches at Peggy’s Cove July 1
#HoofingIt across Canada to fight one of the fastest-growing class of cancers Canadian Neuroendocrine Tumour Society (CNETS) launches fundraising challenge at Peggy’s Cove July 1, 2020 HALIFAX – Neuroendocrine cancer patients, survivors, [...]
Health Canada Approval of NETSPOT®
Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours NETSPOT® is the first and only kit for the preparation of gallium (68Ga) oxodotreotide injection for [...]
New Delivery System for Somatuline® Autogel®
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection) Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline® Autogel® (lanreotide injection) 60, 90, [...]
President’s Message – Summer NETNEWS
It is my pleasure to once again share a quick note on the work of CNETS Canada over the past several months. As always, we have been incredibly busy and are happy to report [...]
CNETS PRIORITIES
SUPPORT
- In-person peer-led support groups meetings
- Dedicated patient email and phone support
- Online private support groups for patients & caregivers
EDUCATION
- Patient and caregiver education sessions across Canada
- Robust online patient educational resources
- Printed educational resources including the NET Reference Guide
- Annual NET Medical and Scientific Meeting
AWARENESS
- Raise awareness of NET cancer to the general public & the medical community
- Participate in World NET Cancer Day Activities
